Nifty
:
23824.10
Sensex
:
76200.68
-278.80 (-1.16%)
-893.39 (-1.16%)
Nifty
Sensex
:
:
23824.10
76200.68
-278.80 (-1.16%)
-893.39 (-1.16%)

Biocon Ltd.

Pharmaceuticals & Drugs - Global

Rating :
62/99

BSE: 532523 | NSE: BIOCON

NSE BSE
423.20
23-Jun-2026
  • Open
  • High
  • Low
  • Previous Close
  •  423.45
  •  432.15
  •  420.3
  •  421.10
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  6927189
  •  2959703005.5
  •  440.4
  •  331

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 68,621.13
  • 177.96
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 80,252.23
  • 0.12%
  • 2.02

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 44.91%
  • 6.17%
  • 10.00%
  • FII
  • DII
  • Others
  • 7.52%
  • 22.74%
  • 8.66%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 16.38
  • 16.40
  • 10.95

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 17.23
  • 18.31
  • 7.33

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 6.29
  • 6.47
  • 29.86

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 61.06
  • 61.66
  • 55.86

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.14
  • 2.88
  • 1.85

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 20.08
  • 16.13
  • 14.39

Earnings Forecasts:

(Updated: 23-06-2026)
Description
2026
2027
2028
2029
Adj EPS
3.83
7.97
12.01
13.82
P/E Ratio
110.50
53.10
35.24
30.62
Revenue
16989.1
19968
22817.1
24795.8
EBITDA
3416.01
4417.62
5310.79
5881.43
Net Income
653.52
1257.62
1869.56
2103.11
ROA
0.93
2.24
2.98
3.23
P/B Ratio
2.28
1.81
1.72
1.72
ROE
2.44
3.66
5.28
5.57
FCFF
302.1
2042.3
2655.18
2575.8
FCFF Yield
0.37
2.52
3.28
3.18
Net Debt
10798.7
9128.16
7154.37
7854.2
BVPS
185.91
234.1
246.45
245.74

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Var%
Dec 25
Dec 24
Var%
Sep 25
Sep 24
Var%
Jun 25
Jun 24
Var%
Net Sales
4,516.60
4,417.00
2.25%
4,173.00
3,821.40
9.20%
4,295.50
3,590.40
19.64%
3,941.90
3,432.90
14.83%
Expenses
3,496.30
3,338.80
4.72%
3,339.50
3,069.60
8.79%
3,460.10
2,905.00
19.11%
3,193.00
2,812.50
13.53%
EBITDA
1,020.30
1,078.20
-5.37%
833.50
751.80
10.87%
835.40
685.40
21.89%
748.90
620.40
20.71%
EBIDTM
22.59%
24.41%
19.97%
19.67%
19.45%
19.09%
19.00%
18.07%
Other Income
52.50
36.90
42.28%
117.30
34.80
237.07%
93.00
32.50
186.15%
79.70
1,134.50
-92.97%
Interest
231.50
212.40
8.99%
209.90
223.40
-6.04%
272.20
225.60
20.66%
276.70
236.00
17.25%
Depreciation
513.40
436.30
17.67%
515.30
425.40
21.13%
473.00
419.90
12.65%
455.00
405.40
12.23%
PBT
247.50
486.80
-49.16%
-67.80
155.90
-
171.30
98.40
74.09%
96.90
1,145.50
-91.54%
Tax
48.90
27.40
78.47%
-16.00
74.80
-
38.50
71.30
-46.00%
7.70
283.70
-97.29%
PAT
198.60
459.40
-56.77%
-51.80
81.10
-
132.80
27.10
390.04%
89.20
861.80
-89.65%
PATM
4.40%
10.40%
-1.24%
2.12%
3.09%
0.75%
2.26%
25.10%
EPS
0.78
2.87
-72.82%
1.08
0.21
414.29%
0.63
-0.13
-
0.23
5.49
-95.81%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Net Sales
16,927.00
15,261.70
14,755.70
11,174.20
8,184.00
7,143.10
6,300.50
5,514.40
4,123.40
3,891.10
3,347.40
Net Sales Growth
10.91%
3.43%
32.05%
36.54%
14.57%
13.37%
14.26%
33.73%
5.97%
16.24%
 
Cost Of Goods Sold
5,690.70
5,197.50
4,897.90
3,663.10
2,718.40
2,243.70
1,989.50
1,896.60
1,636.10
1,446.60
1,290.40
Gross Profit
11,236.30
10,064.20
9,857.80
7,511.10
5,465.60
4,899.40
4,311.00
3,617.80
2,487.30
2,444.50
2,057.00
GP Margin
66.38%
65.94%
66.81%
67.22%
66.78%
68.59%
68.42%
65.61%
60.32%
62.82%
61.45%
Total Expenditure
13,488.90
12,243.00
11,559.00
9,054.70
6,691.40
5,841.00
5,043.50
4,390.60
3,469.00
3,039.90
2,731.50
Power & Fuel Cost
-
377.90
388.90
414.80
316.40
270.30
246.10
239.80
189.00
156.40
184.70
% Of Sales
-
2.48%
2.64%
3.71%
3.87%
3.78%
3.91%
4.35%
4.58%
4.02%
5.52%
Employee Cost
-
3,144.40
2,664.10
2,181.00
1,880.10
1,741.00
1,458.80
1,165.30
931.10
747.00
610.10
% Of Sales
-
20.60%
18.05%
19.52%
22.97%
24.37%
23.15%
21.13%
22.58%
19.20%
18.23%
Manufacturing Exp.
-
1,655.90
2,376.90
1,917.20
1,243.50
1,019.20
864.60
721.20
510.40
519.80
452.90
% Of Sales
-
10.85%
16.11%
17.16%
15.19%
14.27%
13.72%
13.08%
12.38%
13.36%
13.53%
General & Admin Exp.
-
948.10
806.00
359.60
181.50
270.50
182.10
53.00
56.80
21.70
42.60
% Of Sales
-
6.21%
5.46%
3.22%
2.22%
3.79%
2.89%
0.96%
1.38%
0.56%
1.27%
Selling & Distn. Exp.
-
649.90
296.60
221.60
243.80
235.90
266.30
277.50
98.20
107.40
100.80
% Of Sales
-
4.26%
2.01%
1.98%
2.98%
3.30%
4.23%
5.03%
2.38%
2.76%
3.01%
Miscellaneous Exp.
-
269.30
128.60
297.40
107.70
60.40
36.10
37.20
47.40
41.00
100.80
% Of Sales
-
1.76%
0.87%
2.66%
1.32%
0.85%
0.57%
0.67%
1.15%
1.05%
1.49%
EBITDA
3,438.10
3,018.70
3,196.70
2,119.50
1,492.60
1,302.10
1,257.00
1,123.80
654.40
851.20
615.90
EBITDA Margin
20.31%
19.78%
21.66%
18.97%
18.24%
18.23%
19.95%
20.38%
15.87%
21.88%
18.40%
Other Income
342.50
1,355.80
967.50
768.10
690.30
605.20
507.50
414.30
380.90
285.40
231.10
Interest
990.30
897.40
974.40
419.00
67.60
57.70
64.90
70.90
61.50
26.00
29.30
Depreciation
1,956.70
1,687.00
1,568.80
1,113.10
814.20
715.10
552.20
447.80
385.10
277.20
248.70
PBT
447.90
1,790.10
1,621.00
1,355.50
1,301.10
1,134.50
1,147.40
1,019.40
588.70
833.40
569.00
Tax
79.10
457.20
227.40
254.10
211.50
221.50
315.10
212.30
156.90
161.60
142.20
Tax Rate
17.66%
24.23%
14.13%
23.88%
17.77%
19.31%
25.94%
17.49%
26.65%
19.39%
19.49%
PAT
368.80
1,013.30
1,022.50
462.70
648.40
740.50
777.10
905.30
372.40
612.10
550.40
PAT before Minority Interest
385.60
1,429.40
1,297.80
643.00
771.60
846.20
899.80
1,002.60
453.10
688.10
609.10
Minority Interest
16.80
-416.10
-275.30
-180.30
-123.20
-105.70
-122.70
-97.30
-80.70
-76.00
-58.70
PAT Margin
2.18%
6.64%
6.93%
4.14%
7.92%
10.37%
12.33%
16.42%
9.03%
15.73%
16.44%
PAT Growth
-74.20%
-0.90%
120.99%
-28.64%
-12.44%
-4.71%
-14.16%
143.10%
-39.16%
11.21%
 
EPS
2.28
6.25
6.31
2.85
4.00
4.57
4.79
5.59
2.30
3.78
3.40

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Shareholder's Funds
21,644.00
19,783.70
17,866.90
8,432.50
7,626.90
6,705.80
6,098.00
5,180.80
4,837.70
4,033.80
Share Capital
600.30
600.30
600.30
600.30
600.00
600.00
300.00
300.00
100.00
100.00
Total Reserves
20,618.80
18,863.30
16,992.60
7,628.10
6,872.80
5,997.00
5,720.80
4,812.30
4,670.20
3,873.00
Non-Current Liabilities
16,493.30
15,119.80
20,742.30
6,802.70
5,496.90
2,684.70
2,122.30
2,006.50
2,304.60
2,421.30
Secured Loans
10,502.50
11,267.70
13,692.30
2,574.30
1,492.40
1,220.80
1,523.50
1,787.00
2,104.30
2,061.00
Unsecured Loans
1,902.90
1,664.70
1,598.20
1,424.20
1,469.20
1.40
2.10
2.80
3.90
11.40
Long Term Provisions
260.80
237.60
226.50
91.70
106.20
85.80
66.10
49.30
36.00
29.90
Current Liabilities
14,333.80
15,358.80
8,510.70
3,828.00
4,210.10
4,008.00
3,038.50
2,141.30
1,678.30
1,665.70
Trade Payables
6,548.70
6,272.00
3,842.00
1,608.50
1,513.90
1,325.10
1,198.30
1,005.30
739.70
609.80
Other Current Liabilities
3,965.70
6,481.20
1,814.90
1,031.20
1,840.20
1,784.40
1,374.70
870.10
698.20
527.10
Short Term Borrowings
3,454.70
2,149.20
2,480.20
896.00
594.20
667.60
261.20
130.30
97.20
394.90
Short Term Provisions
364.70
456.40
373.60
292.30
261.80
230.90
204.30
135.60
143.20
133.90
Total Liabilities
58,539.60
55,753.40
51,741.80
20,100.70
18,214.60
14,075.80
11,867.70
9,796.30
9,196.70
8,386.60
Net Block
31,963.30
30,643.60
29,467.70
6,569.00
6,363.90
5,971.10
4,471.00
3,699.50
3,625.10
1,748.30
Gross Block
40,804.30
37,930.10
35,321.40
11,233.00
10,220.90
9,147.40
7,095.00
5,873.80
5,436.10
3,403.60
Accumulated Depreciation
8,841.00
7,286.50
5,853.70
4,664.00
3,857.00
3,176.30
2,624.00
2,174.30
1,811.00
1,655.30
Non Current Assets
42,253.40
40,574.20
39,407.80
11,718.40
10,614.20
8,750.80
6,979.20
5,647.70
5,149.00
4,415.70
Capital Work in Progress
8,508.40
7,993.30
7,317.00
4,110.40
2,800.20
2,196.00
1,898.90
1,302.80
839.20
2,239.50
Non Current Investment
679.70
684.10
742.30
370.20
743.20
108.50
182.50
63.80
188.00
25.90
Long Term Loans & Adv.
870.80
892.50
683.20
483.80
436.40
402.00
335.80
437.20
319.70
288.70
Other Non Current Assets
231.20
360.70
1,197.60
185.00
270.50
73.20
91.00
144.40
176.20
112.40
Current Assets
16,286.20
15,179.20
12,334.00
8,382.30
7,600.40
5,325.00
4,888.50
4,148.60
4,047.70
3,970.90
Current Investments
447.30
315.60
1,326.50
1,217.70
1,213.00
857.60
829.30
611.40
1,065.00
874.70
Inventories
4,931.10
4,943.90
4,243.70
2,298.20
1,866.60
1,435.90
1,031.60
722.50
635.30
542.40
Sundry Debtors
5,487.90
6,230.60
3,573.20
2,058.20
1,517.20
1,223.70
1,291.80
1,063.90
883.20
714.50
Cash & Bank
4,120.20
2,258.70
2,400.10
1,747.50
2,049.20
998.60
1,057.20
1,322.80
1,044.30
1,538.60
Other Current Assets
1,299.70
334.40
334.10
660.20
954.40
809.20
678.60
428.00
419.90
300.70
Short Term Loans & Adv.
917.00
1,096.00
456.40
400.50
293.30
349.90
302.30
110.20
48.40
83.60
Net Current Assets
1,952.40
-179.60
3,823.30
4,554.30
3,390.30
1,317.00
1,850.00
2,007.30
2,369.40
2,305.20
Total Assets
58,539.60
55,753.40
51,741.80
20,100.70
18,214.60
14,075.80
11,867.70
9,796.30
9,196.70
8,386.60

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Cash From Operating Activity
4,061.20
2,953.90
1,852.50
1,176.60
1,159.70
1,283.10
1,154.60
662.10
640.00
370.60
PBT
1,886.60
1,525.20
897.10
983.10
1,067.70
870.90
1,002.60
610.00
849.70
751.30
Adjustment
1,711.20
2,356.20
1,685.00
1,245.00
709.60
921.40
472.60
355.70
204.40
42.00
Changes in Working Capital
923.00
-635.20
-501.00
-789.50
-423.80
-165.10
-29.10
-106.50
-211.10
-176.20
Cash after chg. in Working capital
4,520.80
3,246.20
2,081.10
1,438.60
1,353.50
1,627.20
1,446.10
859.20
843.00
617.10
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-459.60
-292.30
-228.60
-262.00
-193.80
-344.10
-291.50
-197.10
-203.00
-246.50
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-234.10
-1,004.50
-14,281.80
-1,699.10
-3,624.70
-1,558.90
-713.80
-684.00
-498.50
-1,141.70
Net Fixed Assets
-393.50
-323.20
-260.40
-284.70
-130.90
744.40
-280.60
-177.90
-215.90
-216.90
Net Investments
-2,064.10
-47.80
-3,990.70
132.70
-459.90
-859.70
105.90
-310.80
-79.30
-3,644.20
Others
2,223.50
-633.50
-10,030.70
-1,547.10
-3,033.90
-1,443.60
-539.10
-195.30
-203.30
2,719.40
Cash from Financing Activity
-1,854.00
-2,332.70
13,048.70
242.10
2,564.00
387.60
-241.70
-239.70
-177.50
1,067.60
Net Cash Inflow / Outflow
1,973.10
-383.30
619.40
-280.40
99.00
111.80
199.10
-261.60
-36.00
296.50
Opening Cash & Equivalents
919.50
1,299.90
653.70
897.00
824.70
659.30
449.00
710.20
757.50
457.50
Closing Cash & Equivalent
2,923.80
919.50
1,294.80
653.70
897.00
824.70
659.30
449.00
710.20
757.50

Financial Ratios

Consolidated /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Book Value (Rs.)
176.73
162.11
146.53
68.53
62.27
54.97
50.17
42.59
39.74
33.10
ROA
2.50%
2.41%
1.79%
4.03%
5.73%
6.94%
9.25%
4.55%
7.64%
7.96%
ROE
7.03%
7.00%
4.98%
9.83%
13.16%
14.26%
18.00%
8.74%
15.37%
16.31%
ROCE
7.43%
7.03%
5.37%
8.30%
11.30%
14.35%
16.11%
8.92%
12.59%
13.93%
Fixed Asset Turnover
0.39
0.41
0.48
0.77
0.74
0.78
0.85
0.73
0.89
1.05
Receivable days
139.43
119.85
91.14
79.19
69.67
72.86
77.96
86.05
74.35
80.16
Inventory Days
117.49
112.31
105.87
92.60
84.38
71.47
58.05
60.00
54.81
53.71
Payable days
450.17
376.86
271.55
209.62
230.92
81.60
81.98
87.98
78.68
71.28
Cash Conversion Cycle
-193.26
-144.70
-74.54
-37.84
-76.87
62.74
54.04
58.07
50.48
62.59
Total Debt/Equity
0.84
0.81
1.01
0.60
0.58
0.40
0.40
0.44
0.48
0.62
Interest Cover
3.10
2.57
3.14
15.54
20.88
19.72
18.12
10.57
33.05
25.90

Annual Reports:

FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016

News Update:


  • Biocon acquires stake in Ampin C&I Power Twelve
    11th Jun 2026, 10:45 AM

    This acquisition aligns with the company’s renewable energy objectives, supporting the procurement of green energy and advancing its decarbonization goals

    Read More
  • Biocon’s arm gets nod from Health Canada for Micafungin for injection
    11th May 2026, 14:12 PM

    The approval will further strengthen the company’s integrated biosimilars and generics portfolio

    Read More
  • Biocon reports 63% fall in Q4 consolidated net profit
    8th May 2026, 14:05 PM

    The total consolidated income of the company increased by 2.59% at Rs 4,569.10 crore for Q4FY26

    Read More
  • USFDA completes Pre-License inspection at Biocon’s biosimilars site
    30th Apr 2026, 09:39 AM

    At the conclusion of the inspection, the USFDA issued a Form 483 with five observations

    Read More
  • Biocon’s Bosaya, Vevzuo get NoC from Health Canada
    21st Apr 2026, 10:30 AM

    Denosumab products play a key role in bone health by increasing bone mass and treating osteoporosis, as well as bone complications associated with cancer

    Read More
  • Biocon’s arm gets USFDA’s nod for Dapagliflozin Tablets
    8th Apr 2026, 10:29 AM

    Dapagliflozin Tablets will be manufactured at Biocon’s FDA-approved facilities, in compliance with global quality and regulatory standards

    Read More
  • Biocon launches Bosaya, Aukelso in US
    7th Apr 2026, 16:42 PM

    Denosumab products play a critical role in bone health, treating osteoporosis and bone complications associated with cancer

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.